LYNX DX, INC.

Lynx Dx is a molecular diagnostics company focused on prostate cancer risk assessment. Founded by renowned clinical researchers from the University of Michigan's urology department, the company developed MyProstateScore (MPS) and its next-generation test MyProstateScore 2.0 (MPS2), which analyzes 18 gene transcripts — including T2:ERG, the most specific prostate cancer biomarker available — to provide individualized, non-invasive risk assessments for clinically significant prostate cancer. By leveraging precision molecular diagnostics, Lynx Dx helps eliminate unnecessary biopsies and supports better clinical decision-making for patients with elevated PSA results.